Alpha Tau Medical Ltd DRTS
News
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
Alpha Tau to Participate in October Investor Conferences
Alpha Tau to Participate in September Investor Conferences
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
